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INTRODUCTION
It is obvious that light entering the eye permits the sensory capacity of vision. The human
species is highly dependent on visual perception of the environment and consequently, the
scientific study of vision and visual mechanisms is a centuries old endeavor. Relatively new
discoveries are now leading to an expanded understanding of the role of light entering the eye -
in addition to supporting vision, light has various nonvisual biological effects. Over the past
thirty years, animal studies have shown that environmental light is the primary stimulus for
regulating circadian rhythms, seasonal cycles, and neuroendocrine responses (Aschoff, 1981 a;
Binkley, 1990; Reiter, 1991). As with all photobiological phenomena, the wavelength, intensity,
timing and duration of a light stimulus is important in determining its regulatory influence on the
circadian and neuroendocrine systems (Aschoff, 198 l b; Cardinali et al., 1972; Takahashi et al.,
1984; Brainard et al., 1983; Brainard et al., 1986). Initially, the effects 3flight on rhythms and
hormones were observed only in sub-human species. Research over the past decade, however,
has confirmed that light entering the eyes of humans is a potent stimulus for controlling
physiological rhythms (Lewy et al., 1980; Moore-Ede et al., 1982; Wurtman et al., 1985;
Czeisler et al., 1986). The aim of this paper is to examine three specific nonvisual responses in
humans which are mediated by light entering the eye: light-induced melatonin suppression, light
therapy for winter depression, and enhancement of nighttime performance. This will serve as a
brief introduction to the growing database which demonstrates how light stimuli can influence
physiology, mood and behavior in humans. Such information greatly expands our understanding
of the human eye and will ultimately change our use of light in the human environment.
STIMULATION OF THE CIRCADIAN AND NEUROENDOCR1NE SYSTEMS BY
LIGHT
In most vertebrate species, it is known that light enters the eyes and stimulates the retina. Nerve
signals are sent from the retina to the visual centers of the brain and permit the sensory capacity
of vision. In addition, neural signals are sent from the retina into the hypothalamus, a non-visual
part of the brain. The hypothalamus is a complex neural region that influences or controls many
basic functions of the body including hormonal secretion, core temperature, metabolism and
reproduction as well as higher cognitive functions such as memory and emotions (Morgane and
Panskep, 1979). Information about environmental light is sent from the retina to a specific part
of the hypothalamus, the suprachiasmatic nucleus (SCN) (Pickard and Silverman, 1981; Moore,
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1983). This partof thebrainis consideredto beafundamentalpartof the"biologicalclock", or
circadiansystem,whichregulatesthebody'sphysiologicalrhythms. Thecircadiansystemis
thoughtto beresponsiblefor controllingdaily rhythmssuchassleepandwakefulness,body
temperature,hormonalsecretionandotherphysiologicalparametersincludingcognitive
function. It is nowclearthat light is theprimarystimulusfor regulatingthecircadiansystem,
althoughotherexternalstimuli suchassound,temperatureandsocialcuesmayalsoinfluence
thebody'stiming functions(Aschoff, 1981a;Binkley, 1990).
TheSCNrelaysretinal informationto manyof themajorcontrolcentersin thenervoussystem
(Moore,1983). Onenervepathwaythatcarriesnon-visualinformationaboutlight extendsfro:n
the SCNto thepinealglandviaamultisynapticpathwaywith connectionsbeingmade
sequentiallyin theparaventricularhypothalamus,theupperthoracicintermediolateralcell
column,andthesuperiorcervicalganglion(Moore,1983;Klein et al., 1983). Cyclesof light
anddarknessrelayedby theretinaentrainSCNneuralactivity which,in turn,entrainsthe
rhythmicproductionandsecretionof melatoninfrom thepineal. In humansandall other
vertebratespeciesstudiedto date,high levelsof melatoninaresecreteduring thenight andlow
levelsarereleasedduringtheday(Binkley, 1990;Reiter,1991;Lewye'_al., 1980;Vaughanet
al., 1976).
THE EFFECTSOF LIGHT INTENSITY AND WAVELENGTH ON MELATONIN
SUPPRESSION
In additionto entrainingmelatoninsecretionfromthepinealgland,light canhaveanacute
suppressive ffectonmelatonin. Specifically,exposureof theeyesto light duringthenight can
causea rapiddecreasein thehighnocturnalsynthesisandsecretionof melatonin(Brainardet al.,
1983;Klein andWeller, 1972;RollagandNiswender,1976). Earlystudiesonhumansdid not
demonstratetheacutesuppressiveinfluenceof light onplasmamelatonin(Vaughanetal., 1976;
Jimersonet al., 1977;Wetterberg,1978;Vaughanetal., 1979). However,Lewy andcolleague:;
(1980)demonstratedthatexposingtheeyesof normalvolunteersto 2500lux of white light
duringthenight inducedan80%decreaseincirculatingmelatoninwithin onehour. In contrasl,
volunteersexposedto 500lux of whitelight exhibitedno significantmelatoninsuppression
(Lewyet al., 1980). Earlierattemptsatsuppressingmelatoninin humanswith light failedwhen
investigatorsusedtypical indoorlight levelsof 100to 800lux (Vaughanetal., 1976;Jimersonet
al., 1977; Wetterberg,1978;Vaughanetal., 1979). Whereas uchtypicalroom light wouldbe
sufficientfor suppressingmelatoninin manyanimalspecies(Binkley, 1990;Reiter, 1991;
Brainardet al., 1983;Klein andWeller, 1972;RollagandNiswender,1976),andwouldbe
adequatefor humanvision, it wasnotenoughto suppressmelatoninin thoseexperiments.
Simplyput,it takesmuchmorelight to suppressmelatoninthanisrequiredfor vision. The
discoverythat muchbrighterlight isneededto suppressmelatoninin humansprovidedthe
groundworkfor numerousstudieson theinternalresponsesof humansto brightartificial light.
However,thenotionthatonly "bright" light candriveneuroendocrineandcircadianresponsesis_
no__ttentirely accurate.
To begin with, the term "bright" refers to a subjective visual sensation and is thus a relative
descriptor (Kaufman, 1984). A 2500 lux light indoors indeed aplbears "bright" relative to typiczl
indoor levels ranging from 100 to 800 lux. In contrast, 2500 lux of light outdoors is relatively
dim compared to daylight at high noon which reaches 100.000 lux (Thorington, 1985). Several
years after it was discovered that light at 2500 lux can suppress melatonin in humans, a study
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was done to more precisely determine the dosages of light needed to suppress melatonin in
normal volunteers (Brainard et al., 1988). In that study, six normal males were exposed to
carefully controlled intensities of monochromatic green light at 509 nm for one hour during the
night. Specifically, the volunteers were continuously exposed to the experimental light between
02:00 and 03:00 hours with their pupils fully dilated by a mydriatic agent, their heads held
steady relative to the light source by an ophthalmologic head holder, and with translucent white
integrating spheres covering both eyes. This procedure produced a constant and uniform
illumination of the whole retina during the entire light exposure. The data from this experiment
(Figure 1) demonstrated that light affects a human hormone in a dose-response fashion: i.e., the
brighter the photic stimulus the greater the suppression of melatonin (Brainard et al., 1988).
It is interesting that all of the stimuli used in this study activated the visual system: both the
volunteers and the experimenters saw all the different light intensities and accurately reported
them to be green. The lower light intensities, however, did not change hormone levels whereas
the higher intensities induced a 60-80% decrease in this hormone. Thus, light that activates
vision does not necessarily cause neuroendocrine change. It appears to be generally true in both
animals and humans that much more light is needed for biological effects than for vision. The
data shown in Table 1 provide the photometric and radiometric values for the stimuli used in
constructing this dose-response function.
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Fig. 1. The dose-response relationship between green monochromatic light (509 nm, 10
nm half-peak bandwidth) exposure of normal volunteers eyes and suppression of the
hormone melatonin (Brainard et al., 1988). Data points indicate mean + SEM.
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TABLE 1 Radiometric and Photometric Stimuli Used in the Melatonin Dose-Response Curve
(Brainard et al., 1988)
_tW/cm ' photons/cm _ photopic lux scotopic lux % melatonin suppression
0.01 9.19 x 10 '3 0.03 0.17 -9.67
0.3 2.76 x 10 '5 1.03 5.25 1.83
1.6 1.47 x 10 '6 5.50 27.98 37.33
5.0 4.59 x 10 '6 17.18 85.90 51.67
13.0 1.19 x 10 _7 44.66 227.37 60.67
The demonstration of the dose-response function for light suppression of melatonin in humans
produced an unexpected result: very bright light is not necessarily, needed for melatonin
suppression. As demonstrated by Table 1, the mean threshold illuminance for suppressing
melatonin was between 5 and 17 lux in normal volunteers - a level of illumination equal to civil
twilight and well below typical indoor light. This means that under the proper conditions, 25 t_
100 times less light can suppress melatonin than originally thought (Lewy et al., 1980). Why did
ambient room light at levels much higher than 17 lux not suppress melatonin in earlier
experiments? In those early studies (Lewy et al., 1980; Vaughan et al., 1976; Jimerson et al.,
1977; Wetterberg, 1978; Vaughan et al., 1979), neither the exposure conditions nor the light
stimuli were optimized. Often the experimental light stimulus consisted of turning on the
overhead light provided with the experimental room. In almost any given room, it is possible to
vary the light illuminance entering the eyes by a factor of 10 simply by changing the direction of
gaze. Thus, in a room characterized as having "typical" illumination levels of 500 lux, the
occupants may be able to see up to 500 lux if they look directly towards the light fixtures, but if
they look at the floor or walls, this light reaching their eyes may be as low as 50 lux.
Furthermore, the pupil of the eye adjusts dynamically to further restrict the amount of light
which reaches the retina. A maximally restricted pupil can reduce the light reaching the retina to
as little as one sixteenth of the light falling on the cornea (Sliney and Wolbarsht, 1980). In
addition, the amount of the retina exposed to the light stimulus varies greatly with the geometry
of the light source and the relative direction of gaze. A recent study by Gaddy (1992) and
colleagues has shown partial retinal exposure is less effective compared to the whole retinal
exposure for suppressing melatonin (Gaddy et al., 1992). Finally; the amount of light entering
the eye can be further reduced by shadowing of the cornea by the bony orbit, squinting and eye
blink. Thus, both behavioral and ocular factors can functionally reduce the amount of light
reaching the retina to a level where it is not effective in suppressing melatonin levels. In the
early studies, we presume that no efforts were made to control pupil size, direction of gaze, and
retinal field exposure since none of these experimental details were reported. Hence, in those
experiments "ordinary room levels of illumination" did not suppress melatonin (Lewy et al.,
1980; Vaughan et al., 1976; Jimerson et al., 1977; Wetterberg, 1978: Vaughan et al., 1979) and
only when much brighter light was used (Lewy et al., 1980) could hormone production be
altered. However, it is clear that very low levels of light can indeed suppress melatonin when
the exposure factors are optimized (Brainard et al., 1988).
In addition to exposure factors and light intensity being critical in determining if a light stimulus
will suppress melatonin, the spectral quality of light is important in determining its relative
biological impact. Studies done on the effects of different wavelengths on hamsters, rats and
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mice suggest that wavelengths in the blue and green portion of the spectrum have the strongest
impact on circadian and neuroendocrine regulation (Cardinali et al., 1972; Takahashi et al. 1984;
Brainard et al., 1984; Brainard et al., 1985; Vaughan et al., 1985; Brainard et al., 1986; Bronstein
et al., 1987; Podolin et al., 1987; Thiele and Meissl, 1987; Millette et al., 1987; Benshoffet al.,
1987; Brainard et al., 1987; Brainard et al., 1991a). Some data have supported the hypothesis
that the rod photopigment rhodopsin is the primary receptor for circadian and neuroendocrine
regulation (Cardinali et al., 1972; Takahashi et al. 1984; Brainard et al., 1984; Podolin et al.,
1987; Thiele and Meissl, 1987; Benshoffet al., 1987; Brainard et al., 1987). In contrast, other
data have suggested that one or more cone photopigments may be involved in these regulatory
effects (Brainard et al., 1984; Podolin et al., 1987; Thiele and Meissl, 1987; Millette et al., 1987;
Benshoffet al., 1987; Brainard et al., 1987). It is important to note that while the highest
sensitivity is in the blue-green range, this does not preclude other wavelengths from participating
in circadian and neuroendocrine regulation. For example, in terms of melatonin suppression,
short wavelengths in the ultraviolet region of the spectrum (Podolin et al., 1987; Benshoff et al.,
1987; Brainard et al., 1987; Brainard et al., 1991a) and longer wavelengths in the red portion of
the spectrum are quite capable of suppressing melatonin in rodents if the intensity is sufficiently
high (Vanecek and Illnerova, 1982; Nguyen et al., 1990; Broker et al., 1990). Further studies are
required to conclusively identify what specific photoreceptors and photopigments are involved in
regulating the circadian and neuroendocrine systems in animals.
Only one study has specifically examined wavelength regulation of melatonin in humans
(Brainard et al., 1988). That study suggested that the peak sensitivity for melatonin suppression
is in the blue-green range as seems to be the case in some lower mammals. It is premature,
however, to draw any conclusions as to what photoreceptors are involved in any nonvisual
physiological regulation in humans.
USE OF LIGHT TO TREAT WINTER DEPRESSION
While research over the past decade has proceeded on the biological effects of light in humans,
concurrent studies have tested the use of light as a therapeutic tool for improving mood and
psychological status of patients diagnosed with winter depression. It has been noted since
antiquity that some individuals are adversely affected by the changing seasons. More recently,
the specific condition of fall and winter depression or Seasonal Affective Disorder (SAD), has
been formally described in the scientific literature (Lewy et al., 1982; Rosenthal et al., 1984;
Rosenthal et al., 1988; Terman et al., 1989a; Terman and Terman, 1992) and been included in
the latest edition of the American Psychiatric Association's diagnostic manual (DSM-III-R,
American Psychiatric Association, 1987). People affected with this malady often experience a
dramatic decrease in their physical energy and stamina during the fall and winter months. As
daylengths become shorter and temperatures become cooler, individuals with SAD often find it
increasingly difficult to meet the demands of life - they can not function well in their jobs or can
not cope with everyday family life. In addition to a general decrease in energy, they experience
emotional depression and feelings of hopelessness and despair. Other symptoms of winter
depression or SAD may include increased sleepiness and need for sleep, increased appetite
(particularly for sweets and other carbohydrates), and a general d.esire to withdraw from society.
People afflicted with this malady often feel compromised in meeting the ordinary demands and
responsibilities of everyday life. Fortunately, among those who are accurately diagnosed with
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SAD,daily light therapyhasbeenfoundto effectively reduce symptoms in many patients (Lewy
et al., 1982; Rosenthal et al., 1984; Rosenthal et al., 1988; Terman et al., 1989a; Terman and
Terman, 1992).
There are now numerous clinics across the United States that offer light therapy for people who
are afflicted with winter depression (Rosenthal, 1990; Society for Light Treatment and
Biological Rhythms, 1991 a). Specific treatment protocols vary somewhat between different
clinics. One frequently used procedure involves a patient sitting at a specific distance from a
fluorescent light panel which provides a 2500 lux exposure when looking directly at the lamp.
The patient is told not to gaze steadily at the bright light, but rather to glance directly at the unit
for a few seconds each minute over a two hour period. During the therapy period, a patient ma) _
read, watch television, work at a computer or do other hand work. Patients often respond to thi:;
therapy after two to seven days of light treatment and continue to benefit as long as the treatment
is repeated daily throughout the months that the individual experiences winter depression
(Rosenthal et al., 1984; Rosenthal et al., 1988; Terman et al., 1989a; Terman and Terman, 1992).
The white light used for treating SAD can be effectively provided by a range of lamp types
including incandescent, cool-white fluorescent, and "sunlight simulating" fluorescent, (Lewy et
al., 1982; Rosenthal et al., 1984; Rosenthal et al., 1988; Terman et al., 1989a; Terman and
Terman, 1992; Yerevanian et al., 1986; Lewy et al., 1987; Terman et al., 1990; Stewart et al.,
1990; Moul et al., 1993; Joffe et al., 1993; Terman et al, 1989b; Avery et al., 1993).
Furthermore, there is an assortment of light devices available for treating SAD. Light therapy
instruments come in a variety of shapes and configurations including workstations (Terman et
al., 1990), head-mounted light visors (Stewart et al., 1990; Moul et al., 1993; Joffe et al., 1993)
and automatic dawn simulators (Terman et al, 1989b; Avery et al., 1993). These devices are
configured to shorten therapeutic time, increase patient mobility or to permit therapy during the
sleep period. Doubtless there will be continued development, diversification and improvement
of light therapy devices and strategies.
THE EFFECTS OF DIFFERENT WAVELENGTHS IN SAD PHOTOTHERAPY
Current evidence supports the hypothesis that light therapy for SAD works by way of light
shining into the eyes as opposed to light on the skin (Wehr et al., 1987). It is not known,
however, what ocular photoreceptors or photopigments mediate the therapeutic benefits of light
in winter depression. To date, three consecutive studies have specifically compared different
portions of the spectrum for clinical efficacy in treating SAD (Brainard et al., 1990; Oren et al.,
1991 ; Stewart et al., 1991). In the first study, 18 patients were treated with an equal photon
dose of white, blue or red light for a period of one week. The photon dose of 2.3 x 10 '_
photons/cm2/sec was selected because this particular photon density of broad spectrum white
light (400-760 nm half-peak bandwidth, Vitalite® lamps, Durotest Corp.) had been shown in
many previous studies to be clinically effective in one week of therapy (Rosenthal et al., 1988;
Terman et al., 1989a). The red and blue light sources used in this study (F40R and F40BB
lamps, Westinghouse Div., Philips Inc.) had half-peak bandwidths of approximately 615-685 run
and 430-465 nm, respectively. Patients' clinical status before and after light therapy was
followed by means of the 21-item Hamilton Depression Rating Scale (HDRS), a standard scale
for measuring symptoms associated with depression (Hamilton, 1967). The results of this stud)'
are illustrated in Figure 2.
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Fig. 2. The bars in this graph indicate mean + SEM Hamilton Depression Rating Scale
values for patients before treatment (hatched bars) and after one week of treatment with
equal photon densities of different light spectra (open bars). Numbers in parentheses
indicate the half-peak bandwidth of the light source (Brainard et al., 1990).
This study was the first step towards defining an action spectrum of light therapy for winter
depression. As shown in Figure 2, one week of light therapy with each of the three light sources
produced an improvement in depression symptoms among the groups of patients tested.
Specifically, the percent drop in mean HDRS scores were 26%, 47% and 27% for the red, white
and blue light sources, respectively. Thus, the photon density emitted from the white light
source elicited a significantly stronger clinical response compared to the results obtained from an
equal photon density from the blue and red light sources (Brainard et al., 1990). This suggests
that broad spectrum white light at this particular photon density is superior to restricted
bandwidths of light in the red and blue portions of the visible spectrum. That result implies that
light sources for SAD light therapy could not be improved by narrowing the wavelengths
provided and shifting them towards either end of the visible spectrum. It is logical, however, to
question the relative efficacy of a green bandwidth of light for treating winter depression.
To resolve that question, a second study was done comparing green light to red light at 2.3 x 10 '5
photons/cmVsec for treating SAD (Oren et al., 1991). The green and red light (F40G and F40R
lamps, Westinghouse Div., Philips Inc.) had half-peak bandwidths of approximately 505-555 nm
and 615-685 nm, respectively. Patients' clinical status before and after one week of light therapy
was followed by means of the 21-item HDRS. The results of this study are illustrated in Figure 3.
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Fig. 3. The bars in this graph indicate mean + SEM HDRS values for patients before treatment
(hatched bars) and after one week of treatment with equal photon densities of green or red light.
Numbers in parentheses indicate the half-peak bandwidth of the light source (Oren et al., 1991).
As illustrated in Figure 3, one week of light therapy with both green and red light sources
produced an improvement in depression symptoms in the groups of patients tested. The percent
reduction in mean HDRS scores was 51% and 30% for the green and red light sources,
respectively. Hence, at this photon density, green light was significantly stronger than the red
light for treating winter depression (Oren et al., 1991). The results of this study (Figure 3)
considered alongside the results from the study comparing red, white and blue light therapy at
the same photon density (Figure 2) suggest that broad spectrum white light and narrower band
green light are equivalent in their capacity to reduce symptoms of SAD. Between the two
studies, white and green light treatments were associated with a 48% and 53% reduction in
HDRS scores, respectively. Comparisons of group responses between different studies,
however, are not conclusive. Are white and green light really equivalent in their
phototherapeutic strength?
To answer that question, 12 patients were given one week of light therapy for SAD with either
green or white light at an equal photon density (Stewart et al., 1991). Since therapy with white
and green light appeared to cause roughly equivalent HDRS reductions across the first two
studies, the experimental photon density was lowered to 1.23 x 10" photons/cm2/sec in the thirci
study. As in the first two studies, patients' clinical status before and after one week of light
therapy was followed by means of the 21-item HDRS. The results of this study are illustrated in
Figure 4.
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As shown in Figure 4, one week of therapy with each of the light sources produced an
improvement in depression symptoms. Specifically, the percent drop in mean HDRS scores was
22% for the green light and 46% for the white light sources. At this lower photon density, white
light was superior to the green light in treating SAD (Stewart et al., 1991). Hence, in this study,
white and green light were not equivalent in their therapeutic efficacy as the preliminary
comparison of the data from the first two wavelength studies suggested.
Together, these three studies form the ground work for determining the action spectrum for
SAD light therapy (Brainard et al., 1990; Oren et al., 1991; Stewart et al., 1991). The traditional
approach to defining a complete action spectrum, however, requires substantially more testing
(Coohill, 1991). A thoroughly defined action spectrum can guide the development of light
treatment devices that emit the optimum balance of wavelengths for treating SAD. Furthermore,
an action spectrum will yield important information about the photosensory mechanism(s)
responsible for the beneficial effects of light therapy. Currently, it is premature to predict what
photopigment(s) or photoreceptor(s) mediate the antidepressant effects of light.
A practical issue debated among SAD researchers concerns the role of ultraviolet radiation (UV)
in light therapy. Most of the early studies on SAD therapy successfully utilized fluorescent
lamps that emitted white light containing a portion of UV wavelengths (Rosenthal et al., 1988;
Terman et al., 1989a). Those early results erroneously led to the suggestion that UV
wavelengths are necessary for successful therapy. The literature, however, shows clearly that
SAD symptoms can be reduced by lamps which emit little or no UV (Yerevanian et al., 1986;
Lewy et al., 1987; Stewart et al., 1990; Moul et al., 1993; Joffe et al., 1993; Brainard et al., 1990;
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Oren et al., 1991 ; Stewart et al., 1991; Lam, 1991). Hence, UV wavelengths do not appear to be
necessary for eliciting positive therapeutic results. Does this rule out UV having any role in
relieving winter depression? Studies demonstrate that UV wavelengths can regulate seasonal
reproduction, melatonin production, and circadian rhythms in some animal species (Brainard et
al., 1985; Vaughan et al., 1985; Podolin et al., 1987; Benshoffet al., 1987; Brainard et al., 1987;
Brainard et al., 1991 a). Furthermore, in normal, healthy humans up to the age of at least 25
years, UV-A can be detected by the visual system (Tan, 1971; Brainard et al., 1992; Sanford et
al., 1992). Although the latest studies show no decrement in therapeutic response when UV is
specifically excluded in SAD treatment, they do not demonstrate that UV is totally
noncontributory. Whether or not UV wavelengths can contribute to the optimum balance of
wavelengths for SAD therapy remains an open question.
The data presented here make it clear that several methodological problems will have to be
overcome before further progress can be made in defining an action spectrum for SAD light
therapy. One complication for the wavelength studies and nearly all studies on SAD involves
the fact that they are done on an outpatient basis. Hence, patient compliance on treatment
timing, frequency and duration cannot be closely controlled even with the most cooperative
subjects. Furthermore, very small changes in gaze direction and patient position relative to the
light source can cause great variability in the amount of light transmitted to the patients' eyes
(Gaddy, 1990; Dawson and Campbell, 1990). Did patients have different gaze behaviors or
different patterns of light usage with the different wavelength light sources? The optimum
method of comparing different wavelengths - or any other photic parameter - for SAD therapy is
to work with more carefully controlled exposures. As demonstrated in the melatonin
suppression studies, tight control of ocular light exposure permits substantially lower light levels
to regulating hormone secretion. Could the general requirement of 2500 lux or more for SAD
therapy be a compensation for differences in patient compliance and exposure variables7
Across the three wavelength studies outlined above, each light treatment produced some
therapeutic improvements. Does this indicate that each light was at least partially effective in
treating SAD symptoms, or are some of the therapeutic benefits of light therapy due to a non-
specific or placebo response? Since patient expectations of treatment outcome are thought to
contribute significantly to the placebo effect, evaluation of expectations before treatment is one
strategy for approaching this question. Prior to any light treatment, subject expectations were
systematically probed in each of the three wavelength studies. In general, all subjects had
positive expectations about the success of light therapy but there were no differences between
the expectations for the different light spectra in these studies (Brainard et al., 1990; Oren et al.,
199 l; Stewart et al., 1991). This evidence supports the idea that some of the therapeutic benefit
of the different light spectra may have been due to a placebo response but that the differential
therapeutic responses to the different light spectra were not merely an extension of the patients'
preconceived beliefs.
In the medical literature it has been well documented that patients with a wide range of disorders
- depression, schizophrenia and anxiety as well as cancer, diabetes and ulcers - can successfully
respond to inactive or placebo treatments (Ross and Olson, 1981; Eastman, 1990a; Eastman et
al., 1993). Hence it would be remarkable if SAD patients did not show some level of placebo
response to light therapy. In fact, therapeutic improvements are almost always observed with
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light treatments regardless of light intensity, wavelength and duration (Rosenthal et al., 1988;
Terman et al., 1989a; Terman and Terman, 1992). Although it is obvious that light therapy
indeed will reduce patients' depression symptoms, the critical question is how much of the
patients' response to light therapy is due to a non-specific placebo response versus a genuine
clinical response? This remains an open question in the SAD field and has been discussed most
insightfully by Eastman (1990a). Unfortunately, until this question is resolved, a more
conclusive action spectrum for SAD phototherapy may not be possible. The inability to
accurately separate placebo responses from genuine clinical antidepressant responses causes an
element of "noise" in phototherapy data which seriously hinders the accurate discrimination of
differential wavelength effects in light therapy.
USE OF LIGHT FOR ENHANCING PERFORMANCE AND TREATING PROBLEMS
OF NIGHT WORKERS
Over the past decade, most of the studies on light therapy have been concerned with winter
depression. Other research, however, has begun to extend the applications of light therapy.
Investigators have had some success in treating certain sleep disorders with phototherapy
(Rosenthal et al., 1990; Dawson et al., 1989). In addition, studies have indicated that individuals
with either non-seasonal depression (Yerevanian et al., 1986; Kripke et al., 1989) or pre-
menstrual syndrome (PMS) may benefit from light therapy (Parry et al., 1987; Parry et al.,
1989). Much more work needs to be done in determining the utility of light for treating these
disorders. It appears that we are entering a frontier of medicine in which man's biological
response to light is being harnessed to alleviate specific illnesses. Such medical developments
have encouraged investigators to explore the possibilities of using light for various domestic or
non-medical applications.
One area of study involves the function and dysfunction of the human circadian physiology
under more challenging situations. Some preliminary studies have tested the use of strategic
light exposure to prevent or ameliorate jet lag (Daan and Lewy, 1984; Wever, 1985; Cole and
Kripke, 1989). The preliminary findings are generally positive and some investigators are
optimistic that light will be a useful tool for quickly resetting the traveler's internal biological
clock and overcoming some of the problems associated with jet travel over multiple time zones.
There is a consensus among scientists however, that the data in this field - as of August, 1991 -
are preliminary and insufficient for a specific prescription on how to best use light for this
modern malady (Society for Light Treatment and Biological Rhythms, 1991 b).
Shift work may pose problems associated with circadian desynchronization analogous to that
found in jet lag (Moore-Ede et al., 1982; U. S. Congress, 1991). Instead of rapidly flying to
distant countries, the shift worker stays in one place but may just as suddenly change the time
period that he is awake or asleep. By the broadest definition, shift workers are individuals who
do not work a standard daytime schedule. Instead, they work nights, evenings, rotating shifts,
split shifts or extended shifts. It is estimated that one out of five full time workers in the United
States (20 million people) is a shift worker (U. S. Congress, 1991).
As Campbell and Dawson (1992) have reported, the two most coinmon and destructive problems
associated with shiftwork are reduced quality of sleep following night work and reduced
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capacity to maintain alertness while at work. Thus, shift work has drawbacks in increased
accidents, decreased production and performance deficits among those who are working at night
when the body has a natural tendency to be asleep. Furthermore, evidence indicates that shift
workers have increased health problems including higher risk to cardiovascular disease,
gastrointestinal distress, as well as cognitive and emotional problems (Moore-Ede et al., 1982;
U. S. Congress, 1991; Campbell and Dawson, 1992; Folkard and Monk, 1985; Eastman, 1990b;
Moore-Ede et al., 1983; Akerstedt et al., 1984). Despite these deleterious effects on worker
health and efficiency, the number of people involved in shift work is likely to increase.
Researchers believe that poor chronobiological adjustment to a permanent or rotating schedule
causes some of these ailments (U. S. Congress, 1991). Not all of these problems, however, are
solely due to a maladapted biological clock. In addition to a desynchronized circadian system,
shift workers generally tend to be chronically sleep deprived and experience domestic stresses
that are more or less independent of circadian adaptation (Moore-Ede et al., 1982; U. S.
Congress, 1991; Folkard and Monk, 1985) Hence, there is no single solution to all of the
problems associated with shift work.
On the frontiers of shift work research, some investigators are attempting to develop strategies 3f
light stimulation to improve circadian entrainment and to enhance performance and alertness in
night workers. In one study, Czeisler and colleagues simulated a.night shift routine in the
laboratory and tested both biological adaptation and behavioral performance under different
lighting stimuli (Czeisler et al., 1990). They found that workers given 7,000 to 12,000 lux of
white fluorescent light during their work hours and complete darkness to sleep in during the
daylight hours, adapted better biologically and had improved alertness and cognitive
performance compared to subjects who worked under 150 lux of light and had no complete
darkout for sleeping during the day (Czeisler et al., 1990). Other studies on simulated shift work
have shown that exposure to bright white fluorescent light at specific times can improve sleep
quality, enhance performance and speed the adjustment of the circadian system (Society for
Light Treatment and Biological Rhythms, 1991b; Campbell and Dawson, 1992; Eastman,
1990b). All of these studies were aimed primarily at finding a means of improving adjustment of
the circadian system, sleep quality and performance of the shift worker. This experimental
approach requires a minimum of 3 to 5 testing days and, under optimum conditions, even longer
test periods to adequately discern circadian and sleep changes.
A different experimental approach has been to examine the immediate effects of light stimuli in a
single night of work or during prolonged periods of work. The principal focus of this research
has been to determine if bright light stimuli can help sustain alertness without degrading
performance. In a study by French and colleagues (1990), healthy young volunteers stayed
awake and worked continuously at a computer for 30 hours, taking only short breaks to eat or l;:o
to the bathroom. While working under 3,000 lux of white fluorescent light during 18:00 to 06:00
hours, the volunteers exhibited significantly improved behavioral and cognitive performance o:a
selected tasks compared to their own performance on a separate occasion under 100 lux. In
addition to these behavioral effects, there were significant differences in the body temperatures,
plasma cortisol levels and plasma melatonin levels in these volunteers under the bright versus
dim light condition (French et al., 1990; Brainard et al., 1991b). A similar study done in a
separate laboratory has also shown that young men doing night work from 21:00 to 08:00 hours
under 5000 lux of white light performed better on selected behavioral tasks versus when they
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worked under light at 50 lux (Hannon et al., 1991). Again, in this study body temperatures and
melatonin levels were significantly influenced by light levels. In these acute studies, it is not
clear how light is influencing performance. Could the correlated biological changes in body
temperature and hormone levels be directly related to improvement in behavioral tests? Is the
circadian system involved in these acute effects of light? Are the acute effects of light due to a
"masking" of circadian rhythms? Clearly, further studies are needed to clarify the mechanism(s)
by which light enhances performance.
There are many occasions when individuals work through the night on an irregular basis, either
by free choice, or by unexpected needs emerging in the home or at work. What are the longer
term consequences of a single night of bright light exposure for improving alertness and
performance? Will the short term gains of enhanced performance or alertness be offset by a
longer term disruption of circadian physiology when the individual returns to a regular schedule?
This new research raises many unanswered questions. As with jet lag applications, there is a
consensus among scientists - as of September, 1991 - that it is still premature to formulate a set
prescription on how to best use light for both short term and long term work applications
(Society for Light Treatment and Biological Rhythms, 1991b; U. S. Congress, 1991). Much
additional work is needed in both laboratory simulations and field tests before the overall
consequences of using bright light stimuli can be determined and the optimum lighting strategy
can be recommended for the varieties of shift work.
As with research on phototherapy for SAD and other disorders, it should be noted that the
studies on using light stimuli to improve problems associated with night work may have
complications of placebo responses. Simply put, most volunteers can readily see that a
manipulation of light is part of the experiment. In such a circumstance, the investigator runs the
distinct risk of finding a placebo reaction to the specific light treatments. There are good
experimental strategies which can help address the potential problem of a placebo response and
some of them are discussed above. One of the best means to avoid placebo problems in lighting
studies is to collect both behavioral and biological data. Whereas behavioral variables and
subjective mood states may be quite susceptible to the volunteers' mental preconceptions,
objective biological variables such as circadian rhythms, hormone levels, electrophysiological
responses, body temperature, urine volume and the like are much'less likely to be directly
influenced by a placebo response. Collecting physiological and behavioral measures together
can greatly improve the reliability of data on nonvisual biological effects of light of light.
CONCLUSION
Experimental research on animals during the past thirty years and on humans in the past decade
confirm that light can strongly influence the physiology and behavior of many species. With
humans, light is a primary stimulus to the circadian system and can regulate many biochemical
and physiological processes in the body. The critical parameters of light intensity and
wavelength needed to provide this nonvisual biological stimulation are still under study. In
addition to these biological effects of light, a high percentage of patients who suffer from winter
depression are responsive to bright light therapy. Other clinical disorders also may be treatable
with light stimuli. Further pioneering studies are now examining the use of light to improve
performance and ameliorate problems associated with shift work. Taken together, these studies
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provide the initial database for a frontier in medicine and biology. Beyond therapeutic
applications, however, what are the potential consequences of this research?
Modem man has become very sophisticated in the specific use of light in his living and working
environment. Currently, building interiors are illuminated for three main purposes: 1) providing
light for visual performance; 2) providing light for visual comfort; and 3) providing light for
aesthetic appreciation of the environment and its contents (Kaufman, 1984; Kaufman, 1987).
The studies discussed here demonstrate that light can also influence human physiology, mood
and behavior. These data may be the seeds for a revolution in architectural lighting. It is
appropriate to begin exploring ways to incorporate these laboratory results into practical
architectural lighting designs. Such designs will need to optimize architectural light for
nonvisual biological stimulation as well as follow the traditional guidelines for providing correct
visual stimulation and comfort. In the long range, this new design consideration is likely to
dramatically alter illumination strategies for homes, factories, offices, schools, hospitals and
most interior living spaces.
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